Nagy MR, Puopolo O, Alston E, et al. MYC amplification and MYC protein expression are poor prognostic markers in pediatric and young adult osteosarcoma. Cancer. 2025;131(22):e70161. doi:10.1002/cncr.70161
Cancer Program
Lightbody ED, Sklavenitis-Pistofidis R, Wu T, et al. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors. Nature cancer. 2025. doi:10.1038/s43018-025-01006-0
Fu C, Saddawi-Konefka R, Chinai JM, et al. In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target. Nature communications. 2025;16(1):8572. doi:10.1038/s41467-025-63592-y
Apfelbaum AA, Morin E, Sturm D, et al. A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. Nature communications. 2025;16(1):7018. doi:10.1038/s41467-025-61820-z
Levesque S, Bauer DE. CRISPR-based therapeutic genome editing for inherited blood disorders. Nature reviews. Drug discovery. 2025. doi:10.1038/s41573-025-01236-y
Zhong S, Wu B, Dubois F, et al. Genomic landscape and immunological profile of glioblastoma in East Asian patients. Cell reports. Medicine. 2025;6(8):102217. doi:10.1016/j.xcrm.2025.102217
Siegel F, Siegel S, Kotýnková K, et al. Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery. 2025. doi:10.1158/2159-8290.CD-25-0605
Shanmugam V, Tokcan N, Chafamo D, et al. Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors. Nature communications. 2025. doi:10.1038/s41467-025-67539-1
Vinyard ME, Rasmussen AW, Li R, Klein AM, Getz G. Learning cell dynamics with neural differential equations. Nature Machine Intelligence. 2025;7. doi:10.1038/s42256-025-01150-3
Sadagopan A, Carson M, Zamurs EJ, et al. Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs. Nature chemical biology. 2025. doi:10.1038/s41589-025-02051-7